Ophthalmology specialty

Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer

1 week ago talkbio0Tagged Alkeus, Biological Factors, Carlos Quezada-Ruiz, Chief Medical Officer, Clinical Research, gildeuretinol, Ophthalmology specialty, Retinal Diseases, Stargardt's disease

Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership

Zhongmou Therapeutics Reports First-in-Human Success of Optogenetic Gene Therapy ZM-02 for Retinitis Pigmentosa

2 weeks ago talkbio0Tagged AAV Vector, First-in-Human Clinical Trial, gene therapy, Ophthalmology specialty, Optogenetic Gene Therapy, PsCatCh2.0, Retinitis Pigmentosa, Vision Restoration, Zhongmou, ZM-02

Zhongmou Therapeutics; Optogenetic Gene Therapy; ZM-02; Retinitis Pigmentosa; First-in-Human Clinical Trial; Vision Restoration; AAV Vector; PsCatCh2.0; Gene Therapy; Ophthalmology

FDA Grants Regeneron Two Eylea HD Approvals in One Day

3 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Regeneron, Retinal Vein Occlusion, RVO, United States Food and Drug Administration

Regeneron; FDA approval; Eylea HD; macular edema; retinal vein occlusion; monthly dosing; aflibercept; ophthalmology; RVO

FDA Approves New Indication and Monthly Dosing for Regeneron’s Eylea HD

3 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Pre-filled Syringe, Regeneron, Retinal Diseases, Retinal Vein Occlusion, United States Food and Drug Administration

FDA approval; Eylea HD; Regeneron; macular edema; retinal vein occlusion; monthly dosing; ophthalmology; aflibercept; retinal diseases; pre-filled syringe

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

3 weeks ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

Eli Lilly Strikes Multiple Deals for Ultra-Rare Eye Disease Gene Therapy and RNAi Partnerships

4 weeks ago talkbio0Tagged AAV-AIPL4, eli lilly, gene therapy, Genetic Leap, Leber congenital amaurosis-4, MeiraGTx, Ophthalmology specialty, partnerships, RNA Interference, SanegeneBio

Eli Lilly; MeiraGTx; gene therapy; Leber congenital amaurosis-4; AAV-AIPL4; Genetic Leap; RNAi; SanegeneBio; ophthalmology; biotech partnerships

Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors

1 month ago talkbio0Tagged Andreas Wallnöfer, Biotechnology, board of directors, Dosage Forms, Drug Development, Hyaluronic Acid anchoring platform, IND-enabling studies, Ophthalmology specialty, Optigo Biotherapeutics, R&D, Retinal Diseases

Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development

Otsuka Acquires Asia-Pacific Rights to 4D Molecular Therapeutics’ Retinal Gene Therapy 4D-150 for $85 Million

1 month ago talkbio0Tagged 4D Molecular Therapeutics ', Asia-Pacific, gene therapy, Macular edema due to diabetes mellitus, Ophthalmology specialty, Otsuka, strategic partnership, Wet Age-Related Macular Degeneration

Otsuka; 4D Molecular Therapeutics; 4D-150; Asia-Pacific rights; gene therapy; wet age-related macular degeneration; diabetic macular edema; $85 million; strategic partnership; ophthalmology